GENPREX GNPX

Andelyn Biosciences will scale manufacturing for Genprex's diabetes gene therapy program. Manufacturing scale-up advances Genprex diabetes gene therapy toward commercialization and supports future revenue potential.

Genprex selects a leading clinical and commercial contract development and manufacturing organization to scale up production of its diabetes gene therapy. Manufacturing scale-up selection supports advancement of Genprex diabetes gene therapy pipeline.

Genprex shares rise after collaboration with Roche Diagnostics. Collaboration with Roche Diagnostics signals major strategic advancement boosting Genprex credibility and trajectory.

Genprex announces collaboration with Roche Diagnostics for biomarker assay validation studies. Roche Diagnostics partnership directly supports Genprex biomarker validation needed for pipeline advancement.

Genprex secures Canadian patent for Reqorsa combo therapy in lung cancer treatment. Canadian patent grant for Reqorsa strengthens Genprex IP position in lung cancer.

Genprex received a Notice of Allowance from the Canadian Intellectual Property Office for a patent on combining Reqorsa gene therapy with PD-1 or PD-L1 antibodies to treat cancer. Canadian patent allowance adds IP protection for Reqorsa combinations but remains limited to one jurisdiction and early-stage approval.

Genprex (GNPX) positive clinical biomarker data for Reqorsa gene therapy published at 2026 ASCO Annual Meeting. Positive biomarker data at major oncology conference signals clinical progress for Reqorsa and lifts Genprex prospects.

Genprex collaborators presented positive preclinical data on a gene therapy for Type 2 diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting. Positive preclinical data for Type 2 diabetes gene therapy at a major conference enhances Genprex's pipeline and market sentiment without immediate transformative effects.

Genprex (GNPX) received a patent grant from the Israel Patent Office for the combination of its Reqorsa® gene therapy and PD-1 antibodies to treat cancer. Patent grant strengthens Genprex's IP protection for Reqorsa® in combination therapies, enhancing competitive positioning and commercialization potential in oncology.

Genprex collaborators will present positive preclinical data on a gene therapy for Type 2 diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting. Positive preclinical data on diabetes gene therapy highlights pipeline progress with moderate potential to influence investor sentiment and competitive positioning.

Genprex (GNPX) announces positive clinical data on biomarkers in patients receiving Reqorsa® gene therapy, to be presented at the 2026 ASCO Annual Meeting. Positive biomarker data from Reqorsa gene therapy presentation at 2026 ASCO represents major clinical progress likely to enhance GNPX's pipeline credibility and investor sentiment.

Genprex (GNPX) signed a sponsored research agreement to study biomarkers that may predict patient response to its Reqorsa gene therapy. Sponsored research on Reqorsa biomarkers could improve patient selection and trial success, moderately advancing pipeline development.

Genprex collaborators to present positive preclinical data on Reqorsa® gene therapy for lung cancer treatment at the 2026 AACR Annual Meeting. Positive preclinical data presentation at AACR highlights pipeline progress but limited by early-stage nature and 2026 timeline.

Genprex secures patents in Japan and the EU for Reqorsa gene therapy combined with immunotherapies to treat cancer, strengthening its intellectual property portfolio. International patents protect Reqorsa's combo therapy applications, enhancing competitive positioning and licensing potential.

Genprex announced that IP Australia intends to grant a patent for its Reqorsa® gene therapy, which is designed to be used in combination with PD-L1 antibodies for cancer treatment. This patent could enhance the company's intellectual property portfolio and strengthen its position in the oncology market. The patent grant represents a significant strategic advancement that could enhance Genprex's competitive positioning in cancer therapies.

Genprex has provided a clinical update on its diabetes gene therapy program, highlighting advancements in its research and development efforts. The company is focused on leveraging its proprietary technology to address diabetes, aiming to improve treatment options and patient outcomes. This update reflects Genprex's commitment to innovation in gene therapy and its potential impact on the diabetes market. The update indicates progress in a key therapeutic area, which may enhance the company's competitive positioning but is not expected to drastically alter its overall trajectory.

Genprex announced positive preliminary preclinical data from its study of GPX-002 in animal models of Type 2 diabetes. The results indicate that GPX-002 may have potential therapeutic benefits for managing the disease, supporting further development and research into its efficacy and safety. Positive preclinical data could significantly impact Genprex's future product development and market positioning in diabetes treatment.

Genprex announced the publication of data from its Acclaim-1 Phase 1 gene therapy clinical trial in Clinical Lung Cancer. The trial evaluated the safety and efficacy of the company's lead product candidate, Oncoprex, in combination with standard therapies for patients with non-small cell lung cancer. Results demonstrated promising outcomes, highlighting the potential of Oncoprex to improve treatment options for this patient population. Promising trial results could significantly enhance Genprex's market position and investor sentiment.

Genprex has announced the addition of a new clinical trial site for its Acclaim-1 and Acclaim-3 lung cancer clinical trials. This expansion aims to enhance patient recruitment and accelerate the development of its lead product candidate, Oncoprex, in combination with immunotherapy for treating non-small cell lung cancer. The new site is expected to facilitate the trials' progress and contribute to the company's overall objectives in oncology. The addition of a clinical trial site is a moderately noticeable influence that may enhance patient recruitment and trial efficiency, impacting the company's development timeline.

Genprex has announced the issuance of a U.S. patent for its Reqorsa® gene therapy, which is designed to be used in combination with PD-L1 antibodies for cancer treatment. This patent is expected to enhance the company's intellectual property portfolio and support its ongoing clinical development efforts in oncology. The patent issuance represents a significant strategic advancement that could enhance Genprex's competitive position in the cancer treatment market.

Genprex announced that the European Patent Office intends to grant a patent for the combination of its Reqorsa® gene therapy and PD-1 antibodies for cancer treatment. This patent could enhance the company's intellectual property portfolio and strengthen its position in the oncology market. The patent grant is a significant strategic move that could enhance Genprex's competitive positioning and market potential in cancer therapies.

Genprex announced positive preclinical data for its Reqorsa® gene therapy targeting lung cancer, presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The findings suggest potential advancements in treatment efficacy, positioning Genprex favorably in the competitive landscape of lung cancer therapies. Positive preclinical data could significantly enhance Genprex's market position and investor sentiment regarding its lung cancer treatment.

Genprex announced a registered direct offering of up to $10.0 million, priced at-the-market under Nasdaq rules. The offering is intended to strengthen the company's financial position and support its ongoing clinical development programs. The offering may provide necessary funding for clinical programs, impacting financial performance moderately.

Genprex announced that collaborators will present positive preclinical data on Reqorsa® gene therapy for lung cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics. This presentation highlights the potential of Reqorsa® in treating lung cancer, showcasing advancements in gene therapy. Positive preclinical data presentation at a major conference could significantly enhance investor sentiment and the company's market position.

Genprex announced a registered direct offering of up to $8.1 million, priced at-the-market under Nasdaq rules. The offering is intended to support the company's ongoing clinical development of its lead product candidate, Oncoprex, for the treatment of non-small cell lung cancer and other cancers. The company aims to use the proceeds for general corporate purposes, including working capital and research and development. The offering may provide necessary funding for clinical development, impacting financial performance and investor sentiment moderately.

Genprex collaborators will present positive preclinical data on Reqorsa® gene therapy for lung cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting advancements in the treatment of this disease. Positive preclinical data could significantly enhance Genprex's competitive positioning and investor sentiment in the oncology market.

GENPREX (GNPX) has been highlighted as one of the most active stocks, indicating increased trading volume and investor interest. The company's recent developments and market movements have drawn attention, suggesting potential shifts in its stock performance. Investors are closely monitoring GNPX for any significant news or updates that could influence its future trajectory. Increased trading activity may affect market sentiment and investor interest, but it does not indicate a fundamental change in the company's operations.

GENPREX (GNPX) has been highlighted as one of the most active stocks, indicating increased trading volume and investor interest. The company is focused on developing innovative therapies for cancer treatment, which may be contributing to its heightened activity in the market. Investors are closely monitoring its progress and potential developments in clinical trials. Increased trading activity suggests moderate investor interest, but no significant developments have been reported that would drastically alter the company's trajectory.

Genprex, Inc. announced its participation in several upcoming investor and industry conferences in September, where it will present its innovative gene therapy platform and discuss its clinical programs. The company aims to engage with investors and industry leaders to enhance visibility and support for its initiatives. Participation in investor and industry conferences can moderately influence market sentiment and visibility for Genprex's clinical programs.

GENPREX (GNPX) has been highlighted as one of the most active stocks, indicating increased trading volume and investor interest. The company's recent developments and market activities have drawn attention, suggesting potential movements in its stock price. Investors are closely monitoring GNPX for any significant news or updates that could influence its market performance. Increased trading activity may affect investor sentiment and stock performance, but it does not indicate a fundamental change in the company's trajectory.